BioSpace News Archive

Quartesian, a multinational Clinical Research Organization serving the biopharmaceutical and medical device industries, announced a multi-year agreement with a leading portfolio medical technology company.

Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B as compared with placebo Quality of life metrics improved with Lomecel-B compared to placebo Complete results being prepared for publication. On track to initiate Phase 2 study in the second half of 2021.

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Sunny Uberoi has joined the organization as its Chief Communications Officer.

mPactAir99™ uses BMT NanoScreen™ technology to create functional, high performance filtration masks that are reusable and washable and engineered to balance outstanding filtration efficiency with the highest rated breathability available.

We are developing the infrastructure of a global zoonotic infectious diseases “alert shield” (ZIDAS) able to successfully manage and control the COVID-19 pandemic; and ultimately prevent future pandemics from developing. This alert shield will operate like a “nuclear shield,” designed to detect incoming nuclear warheads and destroy them before they can be deployed

The American Urological Association and the Urology Care Foundation, the official foundation of the AUA, recognized 14 researchers as recipients of the 2021 Urology Care Foundation Research Scholar Awards.

NTX-001 is a potentially transformative adjunctive treatment for peripheral nerve injuries, using a propriety system for the reconnection of severed nerves. Neuraptive plans to conduct a Phase 2 Multicenter, Randomized, Controlled Study Evaluating the Safety and Efficacy of NTX-001 versus Standard of Care in Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Researchers identify two new genetic variants associated with endocrine dysfunction and eye disease in dogs, providing models for future research in humans

Molecular Targeting Technologies, Inc. (MTTI) announced today the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

- Pivotal trial of rimegepant for the preventive treatment of migraine spotlights reduction of 4.3 monthly migraine days during weeks 9-12 and rapid onset of preventive effects observed within the first week of treatment - Post-hoc analysis of rimegepant in the acute treatment of migraine dosed on an as needed (p.r.n.) basis demonstrated clinically relevant reductions in monthly migraine days over time